Effect of a lipid-lowering nutraceutical on pulse-wave-velocity in hypercholesterolemic patients with or without chronic kidney disease

Open Hypertension Journal

Volumn 5, Issue 1, 2013, Pages 18-22

  Cicero, Arrigo F G ^a   Parini, Angelo ^a   Rosticci, Martina ^a   Brancaleoni, Barbara ^a   Derosa, Giuseppe ^b   Grandi, Elisa ^a   Borghi, Claudio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Arterial stiffness; Berberine; Chronic Kidney Disease; Dietary supplements; Nutraceuticals; Pulse Wave Velocity; Red Yeast Rice

Indexed keywords

ANTILIPEMIC AGENT; BERBERINE; CHOLESTIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NUTRACEUTICAL; TRIACYLGLYCEROL; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; CREATININE; GLUCOSE;

ARTERIAL STIFFNESS; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; OUTPATIENT; PARAMETERS; PRIORITY JOURNAL; PULSE WAVE; QUESTIONNAIRE; RISK; SAFETY; SPHYGMOMANOMETER; AGED; BODY MASS; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAPHY; FEMALE; MALE; SYSTOLIC BLOOD PRESSURE;

EID: 84896874292     PISSN: None     EISSN: 18765262     Source Type: Journal    
DOI: 10.2174/1876526201305010018     Document Type: Article

References (27)

1. Foster MC, Rawlings AM, Marrett E, et al. Cardiovascular risk factor burden, treatment, and control among adults with chronic kidney disease in the United States. Am Heart J 2013; 166(1): 150- 6.
2. Heymann EP, Kassimatis TI, Goldsmith DJ. Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the postsharp era. J Nephrol 2012; 25(4): 460-72.
3. Nijjar PS, Burke FM, Bloesch A, Rader DJ. Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol 2010; 4(4): 248-58.
4. Cicero AF, Borghi C. Evidence of clinically relevant efficacy for dietary supplements and nutraceuticals. Curr Hypertens Rep 2013; 15(3): 260-7.
5. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55(13): 1318-27.
6. Rubin MF, Rosas SE, Chirinos JA, Townsend RR. Surrogate markers of cardiovascular disease in CKD: what's under the hood? Am J Kidney Dis 2011; 57(3): 488-97.
7. Chen SC, Chang JM, Liu WC, http://www.ncbi.nlm. nih.gov/pubmed?term=Tsai YC%5BAuthor%5D&cauthor=true&cauthor_uid=22855129. Brachial-ankle pulse wave velocity and rate of renal function decline and mortality in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6(4): 724-32.
8. Zhao SP, Liu L, Cheng YC, et al. Xuezhikang, an extract of cholestin, protects endothelial function through antiinflammatory and lipid-lowering mechanisms in patients with coronary heart disease. Circulation 2004; 110(8): 915-20.
9. Cheng F, Wang Y, Li J, et al. Berberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans. Int J Cardiol 2013; 167(3): 936-42.
10. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), Catapano AL, Reiner Z, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Perrone Filardi P, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217 Suppl 1: S1-44.
11. Matsushita K, Mahmoodi BK, Woodward M, et al. Chronic Kidney Disease Prognosis Consortium. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012; 307(18): 1941-51.
12. Marazzi G, Cacciotti L, Pelliccia F, et al. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther 2011; 28(12): 1105-13.
13. Cicero AFG, Derosa G, Bove M, Imola F, Borghi C, Gaddi AV. Long-term effectiveness and safety of a nutraceutical based approach to reduce cholesterolemia in statin intolerant subjects with and without metabolic syndrome. Curr Topics Nutrac Res 2009; 7(3-4): 121-6.
14. Pickering TG, Hall JE, Appel LJ et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation 2005; 111(5): 697-716.
15. Tomiyama H, Yamashina A. Non-invasive vascular function tests: their pathophysiological background and clinical application. Circ J 2010; 74(1): 24-33.
16. Cicero AFG, Rosticci M, Gerocarni B, et al. Lactotripeptides effect on office and 24-hour ambulatory blood pressure, blood pressure stress answer, pulse wave velocity and cardiac output in patients with high-normal blood pressure or first degree hypertension: a randomized, double-blind, clinical trial. Hypertens Res 2011; 34(9): 1035-40.
17. Cicero AFG, D'Addato S, Veronesi M, et al. Relationship between blood pressure, cholesterolemia and serum apolipoprotein B in a large population sample: the Brisighella Heart Study. J Hypertens 2012; 30(3): 492-6.
18. Nijjar PS, Burke FM, Bloesch A, Rader DJ. Role of dietary supplements in lowering low-density lipoprotein cholesterol: a review. J Clin Lipidol 2010; 4(4): 248-58.
19. Cicero AFG, Ferroni A, Ertek S. Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipidlowering effects. Expert Opin Drug Saf 2012; 11(5): 753-66.
20. Cicero AFG, Tartagni E, Borghi C. Nutraceuticals with lipidlowering activity: do they have any effect beyond cholesterol reduction? Clin Lipidol 2012; 7(5): 549-59.
21. Trimarco B, Benvenuti C, Rozza F, Cimmino C.S., Giudice R, Crispo S. Clinical evidence of efficacy of red yeast rice and berberine in a large controlled study versus diet. Med J Nutr Metab 2011; 4(2): 133-40.
22. Izzo R, de Simone G, Giudice R, et al. Effects of nutraceuticals on prevalence of metabolic syndrome and on calculated Framingham Risk Score in individuals with dyslipidemia. J Hypertens 2010; 28(7): 1482-7.
23. Cicero AF, Rovati LC, Setnikar I. Eulipidemic effects of berberine administered alone or in combination with other natural cholesterol- lowering agents. A single-blind clinical investigation. Arzneimittelforschung 2007; 57(1): 26-30.
24. Affuso F, Mercurio V, Ruvolo A, et al. A nutraceutical combination improves insulin sensitivity in patients with metabolic syndrome. World J Cardiol 2012; 4(3): 77-83.
25. Pirro M, Lupattelli G, Del Giorno R, et al. Nutraceutical combination (red yeast rice, berberine and policosanols) improves aortic stiffness in low-moderate risk hypercholesterolemic patients. Pharma Nutr 2013; 1(2): 73-7.
26. Affuso F, Ruvolo A, Micillo F, Saccà L, Fazio S. Effects of a nutraceutical combination (berberine, red yeast rice and policosanols) on lipid levels and endothelial function randomized, double-blind, placebo-controlled study. Nutr Metab Cardiovasc Dis 2010; 20(9): 656-61.
27. Cicero AFG, De Sando V, Benedetto D, Cevenini M, Grandi E, Borghi C. Long-term efficacy and tolerability of a largely marketed multicomponent nutraceutical in overweight and normoweight dyslipidaemic patients. Nutrafoods 2012; 11(2): 15-21.